Description

Research Snapshot

What it is:
CJC-1295 with DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). The Drug Affinity Complex (DAC) modification allows CJC-1295 to associate with circulating albumin, substantially extending its biological exposure compared with shorter-acting GHRH analogs.

Researchers study it for:

• Growth hormone signaling
• IGF-1 regulation
• Endocrine physiology
• GHRH receptor activity
• GH/IGF-1 axis signaling
• Long-duration peptide pharmacology
• Metabolic and tissue biology

Target pathway(s):
GHRH Receptor • Growth Hormone Signaling • IGF-1 Axis • Pituitary Somatotroph Signaling

What Is CJC-1295 with DAC?

CJC-1295 with DAC is a modified GHRH analog designed to stimulate the GHRH receptor, which is involved in regulating growth hormone production and release.

The distinguishing feature is its DAC modification. CJC-1295 was engineered to bind to serum albumin after administration, protecting the peptide from rapid clearance and creating a much longer duration of exposure than native GHRH. Early research identified this albumin-binding property as the mechanism behind its extended pharmacokinetic profile.

Human research found an estimated half-life of approximately 5.8–8.1 days, with sustained increases in measured GH and IGF-1 concentrations following exposure. Research has also demonstrated that GH pulsatility can remain present during prolonged stimulation with CJC-1295.

Why Are Researchers Interested?

Current scientific research investigates CJC-1295 with DAC in relation to:

• GHRH receptor activation
• Growth hormone secretion and regulation
• IGF-1 signaling
• Pituitary and endocrine physiology
• GH secretory patterns
• Long-acting peptide pharmacokinetics
• Cellular and metabolic signaling
• GH/IGF-1-associated biomarkers

Its extended activity makes CJC-1295 with DAC particularly interesting for studying sustained GHRH receptor stimulation and downstream GH/IGF-1 signaling over longer experimental periods.

Ongoing research continues to examine CJC-1295 and the broader biological consequences of prolonged GHRH and GH/IGF-1 axis signaling.